RD-227

N/A

Report date: 2021/11/30 15:26:22

Base Information

Drug NameRD-227

Drug Alias NameRD227

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsSolid tumoursLeukemia, Promyelocytic, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Iaso Biotherapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLeukemia, Promyelocytic, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A